Search
RGX-111
go.drugbank.com/drugs/DB17632InvestigationalDeveloped by REGENXBIO Inc., it was investigated for the treatment of mucopolysaccharidosis Type I (MPS I).[L46666]
Mifamurtide
go.drugbank.com/drugs/DB13615ApprovedInvestigationalIn the US, it is currently under investigation that holds orphan drug status for the treatment of osteosarcoma [A31746].
Olsalazine
go.drugbank.com/drugs/DB01250ApprovedOlsalazine is an aminosalicylate and a prodrug of mesalamine (5-aminosalicylic acid, 5-ASA). It was first developed for delivering mesalamine to the colon without the use of sulfapyridine. Olsalazine comprises two mesalamine molecules jo...
Degarelix
go.drugbank.com/drugs/DB06699ApprovedInvestigationalDegarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. Thi...
Dexloxiglumide
go.drugbank.com/drugs/DB04856InvestigationalDexloxiglumide is a selective cholecystokinin type A (CCKA) receptor antagonist in phase III testing by Rottapharm in Europe only, as U.S. trials have been discontinued.
Olenasufligene relduparvovec
go.drugbank.com/drugs/DB16264InvestigationalOlenasufligene relduparvovec is under investigation in clinical trial NCT03612869 (Study of aavrh10-h.sgsh Gene Therapy in Patients With Mucopolysaccharidosis Type IIIA (MPS IIIA)).
Maribavir
go.drugbank.com/drugs/DB06234ApprovedInvestigationalMaribavir is an inhibitor of the cytomegalovirus (CMV; HHV5) pUL97 kinase which is used to treat CMV infections in patients post-transplantation. Most standard CMV therapies, such as ganciclovir or foscarnet, target CMV DNA polymerase - ...
Gramicidin D
go.drugbank.com/drugs/DB00027ApprovedInvestigationalGramcidin D is a heterogeneous mixture of three antibiotic compounds, gramicidins A, B and C, making up 80%, 6%, and 14% respectively all of which are obtained from the soil bacterial species Bacillus
Ropinirole
go.drugbank.com/drugs/DB00268ApprovedInvestigationalIn 2005, it was the first drug approved in the US for the management of primary moderate to severe restless legs syndrome [A174547].
Pentetic acid
go.drugbank.com/drugs/DB14007ApprovedInvestigational[L2242] DPTA was developed by the pharmaceutical company CIS US and FDA approved on April 14, 2004.[L1469]